![A look at the jets flying high above the Paris Air Show [PHOTOS]](https://breakingdefense.com/wp-content/uploads/sites/3/2025/06/Rafale_02-scaled-e1750268097167.jpg?#)
Zealand Pharma’s GLP-1/GLP-2 candidate linked to 11.6% weight loss after 28 weeks
Zealand Pharma is back with updated findings for its GLP-1/GLP-2 receptor dual agonist, finding mean body weight reductions rose to 11.6% for a higher dosing regimen after 28 weeks in a phase 1b trial.
Zealand Pharma is back with updated findings for its GLP-1/GLP-2 receptor dual agonist, finding mean body weight reductions rose to 11.6% for a higher dosing regimen after 28 weeks in a phase 1b trial.
